Ligand Pharmaceuticals Incorporated (LGND) Social Stream
LIGAND PHARMACEUTICALS INC (LGND) Price Targets From Analysts
Use the tables below to see what analysts covering LIGAND PHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 5 | $310 | $170 | $206 | $72.63 | 183.63% |
| 2022-02-18 | 5 | $310 | $180 | $210.4 | $72.63 | 189.69% |
| 2022-05-05 | 5 | $310 | $153 | $201.6 | $72.63 | 177.57% |
| 2022-08-09 | 3 | $310 | $130 | $195.5 | $72.63 | 169.17% |
| 2022-09-02 | 4 | $310 | $130 | $193 | $72.63 | 165.73% |
| 2022-10-25 | 4 | $175 | $130 | $147.5 | $72.63 | 103.08% |
| 2022-11-21 | 4 | $175 | $120 | $140 | $72.63 | 92.76% |
| 2022-12-14 | 4 | $135 | $85 | $117.5 | $72.63 | 61.78% |
| 2022-12-23 | 4 | $135 | $90 | $118.75 | $72.63 | 63.5% |
| 2023-02-21 | 4 | $135 | $90 | $110 | $72.63 | 51.45% |
| 2023-03-02 | 3 | $135 | $95 | $111.25 | $72.63 | 53.17% |
| 2023-05-05 | 2 | $135 | $95 | $111.75 | $72.63 | 53.86% |
| 2023-06-02 | 3 | $144 | $95 | $114 | $72.63 | 56.96% |
| 2023-08-10 | 3 | $144 | $95 | $111.5 | $72.63 | 53.52% |
| 2023-11-09 | 3 | $144 | $95 | $116.333 | $72.63 | 60.17% |
| 2023-11-13 | 4 | $144 | $95 | $111.5 | $72.63 | 53.52% |
The Trend in the Analyst Price Target
Over the past 33 months, LGND's average price target has gone down $113.17.
LGND reports an average of 75.65% for its upside potential over the past 38 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-21 | 4 | 135 | 90 | 110.00 | 70.88 | 55.19% |
| 2023-05-05 | 2 | 135 | 95 | 111.75 | 79.33 | 40.87% |
| 2023-06-02 | 3 | 144 | 95 | 114.00 | 75.31 | 51.37% |
| 2023-07-25 | 3 | 144 | 95 | 111.50 | 67.30 | 65.68% |
| 2023-11-13 | 4 | 144 | 95 | 111.50 | 55.17 | 102.1% |
LGND Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 4 | 0 | 0 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
Over the past 15 months, LGND's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for LGND as an investment opportunity.
- LGND has a greater number of analysts covering the stock than 282.81% of all US stocks.
- In terms of how LIGAND PHARMACEUTICALS INC fares relative to stocks in the mid market cap category, note that its average analyst price target is higher than 1965.68% of that group.
- LGND has a higher upside potential (average analyst target price relative to current price) than 1645.31% of stocks in the mid market cap category.
- LIGAND PHARMACEUTICALS INC's variance in analysts' estimates is lower than -683.96% of Pharmaceutical Products stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to LIGAND PHARMACEUTICALS INC are ARWR, IMGN, and HRTX.
View All Top Stocks by Price Target
Make investment decisions regarding LGND using the data that counts. Try POWR Ratings for free.